



NLCA indicators

Reviewed January 2018

Audit measure	New standard
DATA COMPLETENESS	
Valid performance status (PS) and stage	≥90%
Patients with stage I–II and PS 0–1, completeness for FEV1 and FEV1% predicted	>75%
PROCESS	
Proportion of patients seen by lung CNS	≥90%
Proportion of patients where lung CNS present for diagnosis	≥80%
Proportion of patients with pathological confirmation of lung cancer for stage I–II and PS 0–1	≥90%
Proportion of patients with pathological confirmation of lung cancer with PS 0–2	≥80%
Proportion of patients where the pathology code is NSCLC-NOS	<15%
Proportion of patients receiving PET-CTscan before surgery or radical radiotherapy	≥90%
TREATMENT & OUTCOME	
Proportion of patients receiving anticancer treatment	>60%
Proportion of patients with PS 0–1 having anticancer treatment	>80%
Proportion of patients with NSCLC undergoing surgery	>17%
Proportion of NSCLC stage IIIB/IV and PS 0–1 who get systemic anticancer treatment	>65%
Proportion of SCLC patients receiving chemotherapy	>70%
Proportion of patients receiving chemotherapy for SCLC starting treatment within 2 weeks of pathological diagnosis	≥80%
Proportion of patients with stage I–II NSCLC and PS 0–2 receiving treatment with curative intent	>80%

Glossary

CNS: cancer nurse specialist

FEV1: forced expiratory volume in 1 second

NSCLC: non-small cell lung cancer

NOS: not otherwise specified

EGFR: epidermal growth factor receptor

PET - CT: positron emission tomography – computed tomography

SCLC: small cell lung cancer

PS: performance status

For more information contact NLCA@rcplondon.ac.uk